An Exciting Time in CDI: Approvals, Approaches and Anticipation

The therapies for Clostridioides difficile infection (CDI) saw many developments in recent months and there are more exciting things to come.


slideshow image

Back in November, the FDA approved its first fecal microbiota product, RBX2660 (Rebyota). RBX2660 was approved to prevent recurrent CDI in adult patients who have already completed an antibiotics regimen for recurrent CDI.

CDI saw quite a number of developments in 2022, especially with the approval of first-ever fecal microbiota, RBX2660, for C difficile recurrence at the end of the year.

There has been research looking at different approaches and the economics of CDI. In addition, there is another prospective approval pending for CDI this year.

Check out our slideshow to find more information on the approval, a differing approach, the economics of CDI, and what’s ahead.

To read the articles for the individual slides, click on the individual slides below:

Slide 1

Slide 2

Slide 3

Slide 4

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.